Predicted average and marginal costs of an annual IVM/ALB MDA programme to control disease or eliminate LF transmission in the Republic of Tanzania.

1Represents a programme targeted at disease control assumed to occur when the mf prevalence is reduced long-term (for at least 10 years) to below 3.99% (figure 2a). For a baseline prevalence of 11.95% mf prevalence, it is predicted to take up to 5years of MDA with IVM/ALB to reduce infection prevalence to 2.3% to achieve this objective at 80% coverage.
2Represents a programme to eliminate parasite transmission assumed to occur when the mf prevalence is reduced to just below 0.5%. For a baseline prevalence of 11.95% mf prevalence, it is predicted to take up to 10 years of MDA with IVM/ALB to achieve this target at 80% coverage.
3The full economic cost of the programme, including the cost of donated drugs and programme delivery costs borne by the Government estimated at $0.70 for treating each individual.
4Excludes the cost of donated drugs. Estimate of drug costs to total programme cost obtained from ref (24.2%) is used in calculating only the additional Government cost involved in delivering the MDA programme. Effectively, this decreases the per capita cost of treating an individual from $0.70 per individual for the total cost estimation to $0.53 per individual for the Government costs only estimation.
5Addition individuals cured of mf and the total and average marginal costs of curing these individuals to achieve parasite transmission elimination from a programme targeted at disease control.